Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
What Is AOD-9604? Benefits, Research & Safety
A modified fragment of human growth hormone specifically researched for its fat-metabolising properties without the growth-promoting effects of full HGH.
Also known as:
Anti-Obesity Drug 9604
HGH Fragment 177-191
Tyr-hGH Fragment 177-191
UK summary: Not a licensed UK medicine. A modified fragment of growth hormone marketed for fat loss. Earlier obesity development did not produce a licensed product; human evidence for normal adults is limited. Captured by WADA prohibited classes for growth-related peptides.
Quick Facts
Category
Fat Loss & Metabolic
Half-Life
Relatively short; specific pharmacokinetic data limited
UK Status
Not licensed as a medicine. Research compound only.
EU Status
Not approved for human therapeutic use.
Overview
AOD-9604 is a synthetic peptide consisting of a modified fragment of human growth hormone (hGH), specifically the C-terminal region spanning amino acids 177-191 with an additional tyrosine residue at the N-terminus. This peptide was developed to isolate the fat-metabolising properties of growth hormone while eliminating its growth-promoting and diabetogenic effects.
The development of AOD-9604 was based on the observation that the lipolytic (fat-burning) activity of growth hormone is mediated by a different region of the molecule than its growth-promoting effects. By isolating this specific fragment, researchers aimed to create a compound that could promote fat loss without the side effects associated with full growth hormone administration.
Research has demonstrated that AOD-9604 stimulates lipolysis (the breakdown of fat) and inhibits lipogenesis (the formation of new fat). Importantly, studies suggest it does not affect blood glucose levels or stimulate the growth of tissues—distinguishing it from full growth hormone.
AOD-9604 has progressed through clinical trials for obesity treatment, though it has not achieved regulatory approval for this indication. The peptide has also been investigated for cartilage regeneration and is approved in Australia as a complementary medicine for joint support.
Evidence standards summary
AOD-9604 — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
CLimited human evidenceOverall grade against our evidence grading methodology.
Not a licensed UK medicine. A modified fragment of growth hormone marketed for fat loss. Earlier obesity development did not produce a licensed product; human evidence for normal adults is limited. Captured by WADA prohibited classes for growth-related peptides.
02Human evidence grade
DAnimal/cell evidence onlyStrength of evidence from published human trials.
03Preclinical evidence grade
CLimited human evidenceAnimal-model and in-vitro evidence quality.
04Regulatory status
- UK: Not licensed as a medicine. Research compound only.
- EU: Not approved for human therapeutic use.
- Notes: AOD-9604 is approved in Australia as a complementary medicine ingredient for joint function (oral products). It failed Phase III trials for obesity and is not approved for weight loss anywhere. WADA has not specifically listed it but athletes should exercise caution.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Targeted fat loss without affecting muscle, glucose, or growth.
- Stack it with semaglutide for accelerated fat loss without the side effects.
- Cosmetic-approved fat loss in Australia or Europe.
- Safe long-term daily injection at home.
07Common internet claims
- Marketed as the targeted-fat-loss peptide for stubborn body areas.
- Often sold alongside semaglutide or tirzepatide in injectable bundles.
- Promoted in cosmetic clinic packages as a body-sculpting add-on.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Burns fat without affecting blood sugar” | C | Limited | High | Small human studies in obesity have shown limited fat-loss effect; AOD-9604 did not progress to a licensed obesity product. |
| “Safer than full HGH for body composition” | E | No | High | Comparative-safety claims need comparative trials. AOD-9604 is unlicensed; HGH is a controlled medicine. |
| “Enhances semaglutide / Mounjaro weight loss” | E | No | High | No robust human RCTs of the combination exist. See our /stacks/claim-reviews/semaglutide-aod-9604 page. |
| “Approved for cosmetic fat loss” | E | No | High | AOD-9604 has no UK marketing authorisation for fat loss. |
09Safety uncertainty score
High
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Injection site reactions.
- Headache, fatigue, and nausea reported anecdotally.
- Theoretical risk from chronic GH-fragment exposure (insulin resistance, fluid retention).
- Unknown effects when combined with licensed GLP-1 agonists.
11Drug-interaction uncertainty
High
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
WADA: Prohibited in sportWADA strict-liability framing applies.
13UK legal position
UK: Unlicensed (UK)
Not licensed as a medicine. Research compound only.
Read the full UK legal guide → Are peptides legal in the UK?
14EU legal position
Not approved for human therapeutic use.
15What this page cannot tell you
- Whether a UK-purchased AOD-9604 vial actually contains the labelled peptide.
- What clinically meaningful fat-loss effect (if any) it has in normal-weight adults.
- Whether stacking with semaglutide or tirzepatide increases risk.
- What the WADA in-competition status is for athletes — growth-related peptides are class-prohibited.
16Last reviewed
17Citation quality score
CLimited human evidenceQuality of the sources we cite, graded against the evidence grading methodology.
18Research gaps
- Phase 3 obesity trial was not successfully completed.
- No published RCT data for AOD-9604 in normal-weight adults seeking cosmetic fat loss.
- Long-term safety beyond a few weeks is unstudied.
- Combination safety with GLP-1 agonists or other weight-loss drugs not assessed.
19Safer alternatives / established care pathways
- Licensed Wegovy (semaglutide) via NHS or GMC-registered prescriber.
- Licensed Mounjaro (tirzepatide) via NHS specialist or registered private clinic.
- Structured diet, resistance training, and cardio — the only evidence-based body-recomposition stack.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is AOD-9604 a licensed UK medicine for any condition?
- What does the human evidence actually show for adults at a healthy weight?
- If a clinic is pairing AOD-9604 with a licensed GLP-1, what's the regulatory implication?
- What are the known and theoretical risks of long-term growth-hormone-fragment exposure?
- If I'm an athlete, what's my anti-doping exposure?
Discovery & History
AOD-9604 was developed by Professor Frank Ng and colleagues at Monash University in Melbourne, Australia, during the 1990s. The research was conducted in collaboration with Metabolic Pharmaceuticals Limited.
The development was based on earlier observations that human growth hormone's metabolic effects could be separated from its growth-promoting effects. Researchers identified the C-terminal region of hGH as being responsible for its lipolytic activity and synthesised a peptide fragment corresponding to this region.
Initial preclinical studies in the late 1990s and early 2000s demonstrated that AOD-9604 could reduce body fat in obese mice without affecting growth or IGF-1 levels. These promising results led to human clinical trials.
Phase II clinical trials were conducted for obesity treatment, showing some evidence of fat reduction. However, Phase III trials did not meet their primary endpoints, and development for obesity was not pursued further.
Subsequently, AOD-9604 was investigated for cartilage repair and joint health applications. In 2019, Australia's Therapeutic Goods Administration (TGA) approved AOD-9604 as a complementary medicine ingredient for joint function.
Mechanism of Action
AOD-9604 works through mechanisms distinct from those of full growth hormone:
**Lipolysis Stimulation**
AOD-9604 stimulates the breakdown of stored triglycerides in adipose tissue, releasing fatty acids into the bloodstream for use as energy. This lipolytic effect is similar to that of full growth hormone but occurs without stimulating IGF-1 production.
**Lipogenesis Inhibition**
The peptide appears to inhibit the conversion of non-fat food sources into body fat, reducing the formation of new adipose tissue. This dual action—promoting fat breakdown while inhibiting fat storage—underlies its potential for body composition modification.
**Beta-3 Adrenergic Receptor Interaction**
Research suggests AOD-9604 may interact with beta-3 adrenergic receptors, which are involved in fat metabolism and thermogenesis. This receptor pathway is distinct from growth hormone's primary signalling mechanisms.
**Glucose-Neutral Effects**
Unlike full growth hormone, AOD-9604 does not appear to significantly affect blood glucose levels or insulin sensitivity in research to date. This is because it does not stimulate the production of IGF-1.
**Cartilage Effects**
More recent research has explored AOD-9604's effects on cartilage, suggesting potential for stimulating chondrocyte activity and proteoglycan synthesis, which may benefit joint health.
Researched Benefits
Based on preclinical and clinical research findings:
- 1Stimulation of fat breakdown (lipolysis) without affecting muscle tissue
- 2Inhibition of new fat formation (lipogenesis)
- 3No apparent effect on blood glucose or IGF-1 levels
- 4Potential support for cartilage health and joint function
- 5No growth-promoting effects that could be problematic
- 6Possible regenerative effects on connective tissues
Claim vs Evidence
How popular claims about AOD-9604 stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Burns fat without affecting blood sugar” | C | Limited | High | Small human studies in obesity have shown limited fat-loss effect; AOD-9604 did not progress to a licensed obesity product. |
| “Safer than full HGH for body composition” | E | No | High | Comparative-safety claims need comparative trials. AOD-9604 is unlicensed; HGH is a controlled medicine. |
| “Enhances semaglutide / Mounjaro weight loss” | E | No | High | No robust human RCTs of the combination exist. See our /stacks/claim-reviews/semaglutide-aod-9604 page. |
| “Approved for cosmetic fat loss” | E | No | High | AOD-9604 has no UK marketing authorisation for fat loss. |
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | 250-500 mcg per day (based on clinical trial protocols) |
| Frequency | Once daily, typically in the morning on an empty stomach |
| Duration | 12-24 weeks in clinical research settings |
| Notes | These protocols are derived from clinical trial data. AOD-9604 is not approved for weight loss. Any use should be under medical supervision. The peptide is typically administered via subcutaneous injection. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (most common in research)
- Oral administration (being developed for joint health products)
| Half-Life | Stability |
|---|---|
| Relatively short; specific pharmacokinetic data limited | Stable in lyophilised form; should be refrigerated after reconstitution |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Injection site reactions
- Mild headache
- Temporary flu-like symptoms
- Nausea in some cases
Rare Risks & Concerns
- Unknown long-term effects
- Potential for antibody development
- Effects on other metabolic parameters not fully characterised
Contraindications
- Pregnancy and breastfeeding
- Active malignancy
- Children and adolescents
- Severe metabolic disorders
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed as a medicine. Research compound only.
🇪🇺 European Union
Not approved for human therapeutic use.
AOD-9604 is approved in Australia as a complementary medicine ingredient for joint function (oral products). It failed Phase III trials for obesity and is not approved for weight loss anywhere. WADA has not specifically listed it but athletes should exercise caution.
Clinical Studies Summary
Effects of AOD9604 on Fat Metabolism in Obese Zucker Rats
Preclinical study demonstrating AOD-9604's ability to reduce body fat without affecting growth in animal models.
Mol Cell Endocrinol. 2000;159(1-2):143-55View on PubMed
Phase II Clinical Trial of AOD9604 in Obese Adults
Human study investigating safety and efficacy of AOD-9604 for weight management.
J Clin Endocrinol Metab. Various publicationsView on PubMed
Looking for AOD-9604?
Source research-grade AOD-9604 from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about AOD-9604
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is AOD-9604 a licensed UK medicine for any condition?
- What does the human evidence actually show for adults at a healthy weight?
- If a clinic is pairing AOD-9604 with a licensed GLP-1, what's the regulatory implication?
- What are the known and theoretical risks of long-term growth-hormone-fragment exposure?
- If I'm an athlete, what's my anti-doping exposure?
UK regulatory & safety context
Related Research Guides
Peptide Comparisons
Related Peptides
Semaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreTesofensine
A triple monoamine reuptake inhibitor originally developed for neurological conditions, now researched for its potent effects on appetite suppression and weight loss.
Learn moreHGH Fragment 176-191
A fragment of human growth hormone corresponding to amino acids 176-191, researched specifically for its fat-metabolising properties.
Learn moreCJC-1295
A synthetic growth hormone-releasing hormone analogue designed for extended half-life and sustained growth hormone secretion.
Learn more